Celcuity Incis A Clinical Stage Biotechnology Company Based In Minneapolisminnesotafounded In 2011The Company Employs 87 People And Specializes In Developing Precision Diagnostics And Targeted Therapies For Solid Tumorswith A Focus On Breast And Prostate Cancers Celcuity S Key Offerings Include The Celsigniaa C Diagnostic Platformwhich Analyzes Live Tumor Cells To Identify Patients Who May Benefit From Specific Targeted Therapiesparticularly For Her2 Low Breast Cancerthe Company Is Also Advancing Gedatolisiba Pan Pi3K Mtor Inhibitor Currently In Phase 3 Trials For Hrher2Advanced Breast Canceradditionallycelcuity Provides Precision Oncology Testing Services And Engages In Research Collaborations With Institutions And Pharmaceutical Companiesincluding A Partnership With Pfizer With A Mission To Extend Patient Lives Through Precision Oncologycelcuity Targets Underserved Populations And Operates Under A Hybrid Model That Combines Diagnostic Development With Therapeutic Innovationthe Company Generated $3 45 Million In Revenue In 2023 And Holds $22 3 Million In Cash Reserves As Of Q4 2023
